BioSpace News Archive

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that it will host a Key Opinion Leader (KOL) webinar on the acute treatment of migraine, DHE, and STS101 on Thursday, June 16, 2022 at 10:30 a.m. ET.

TC Biopharm PLC announced the closing of its previously announced underwritten public offering of 10,000,000 American Depositary Shares, each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses.

Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO® (diazepam nasal spray) CIV.

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provide top-line results from the Phase 3 TRANQUILITY-2 Trial of reproxalap in dry eye disease.

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology .

Bristol Myers Squibb to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference.

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.

mRNA-1010 is Moderna’s first seasonal influenza vaccine candidate to enter a Phase 3 trial mRNA-1010 is one of several influenza vaccine candidates being developed in Moderna’s respiratory portfolio.

MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers.